Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05193292
Other study ID # FUSCC-CamreTrastumCRC
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date January 2022
Est. completion date January 2025

Study information

Verified date December 2021
Source Fudan University
Contact Zhe Zhang, PHD
Phone 8621-64175590
Email zhangzhe2010fduscc@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aimed to evaluate the efficacy and safety of camrelizumab combined with trastuzumab and chemotherapy in Patients with HER2-positive advanced colorectal cancer


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 77
Est. completion date January 2025
Est. primary completion date January 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subjects has voluntarily agreed to sign the informed consent and have good compliance and are willing to cooperate with follow-up. 2. Age 18 years or older, male or female. 3. Have a life expectancy of at least 3 months. 4. Histologically confirmed diagnosis of unresectable recurrent or metastatic HER2 positive colorectal cancer. 5. HER2 positivity defined as the colorectal cancer-specific HERACLES diagnostic criteria or NGS sequencing of tumor tissue/blood samples showed HER2 amplification. 6. Patients have not received systemic anti-cancer treatment in the past or had disease progression more than 6 months after receiving after (neo)adjuvant treatment could be enrolled or failure of first-line therapy or completion of (new) adjuvant therapy to disease recurrence less than 6 months. 7. At least one measurable or evaluable lesion, as defined by RECIST 1.1 criteria. 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 9. The functional level of the major organs must meet the following requirements:(1)Blood routine: neutrophils (ANC) =1.5×10^9/L; platelet count (PLT)=90×10^9/L; hemoglobin (Hb) =90 g/L; (2)Blood biochemistry: TBIL=1.5×ULN; ALT and AST=2.5×ULN; Cr=1.5×ULN and creatinine clearance=50 mL/min (Cockcroft-Gault formula); for subjects with liver metastasis: TBIL=3×ULN; ALT and AST=5×ULN; (3)Patients was not receiving anticoagulation therapy (INR = 1.5 or aPTT = 1.5 × ULN). If the patient received prophylactic anticoagulation therapy and the INR = 2 × ULN within 14 days before the start of the study and the aPTT/PPT is within the normal range could be enrolled; (4)Left ventricular ejection fraction (LVEF) =55% (within 28 days). 10. Female subjects of childbearing age or male subjects whose sexual partners are females of childbearing age must take effective contraceptive measures throughout the treatment period and 6 months after the treatment period. Exclusion Criteria: 1. Have previously received any co-stimulatory or co-inhibitory T cell receptor antibody or drug therapy, including PD-1, PD-L1, PD-L2, CD137, CTLA-4, etc. 2. Have previously received anti-HER2 targeted therapy (monoclonal antibody or small molecule TKI). 3. Have any active autoimmune diseases or autoimmune diseases in the past 2 years. 4. Have used immunosuppressive drugs within 4 weeks before the first dose of study drug treatment. 5. Allergic to any monoclonal antibody or chemotherapeutic drug preparation component. 6. Receive a live attenuated vaccine within 4 weeks before the first dose of study drug treatment. 7. Known symptomatic central nervous system metastases and/or cancerous meningitis. If subjects with brain metastases who have been treated in the past are in stable condition, they could be enrolled. 8. Pleural and abdominal effusion requiring clinical treatment, or third interspace effusion. 9. Suffering from congenital or acquired immune deficiency. 10. Known history of human immunodeficiency virus (HIV) infection. 11. Subjects who have received allogeneic tissue/solid organ transplantation. 12. Known to have active tuberculosis. 13. Known to have acute or chronic active hepatitis B or acute or chronic active hepatitis C. 14. Severe infections that are active or poorly clinical controlled. 15. Known history of (non-infectious) pneumonia requiring steroid treatment or currently suffering from pneumonia. 16. Other poorly controlled comorbidities. 17. Pregnancy or breastfeeding or planning to pregnancy or childbirth during the study period. 18. Have uncontrolled cardiac clinical symptoms or diseases. 19. Malignant tumors that are progressing or require active treatment in the past 5 years, except for the following: (1) Malignant tumors that have been completely relieved for at least 2 years before enrollment and no other treatment is required during the study period; (2) Non-melanoma skin cancer or malignant freckle-like nevus that has been adequately treated and has no evidence of disease recurrence; (3) Carcinoma in situ with adequate treatment and no evidence of disease recurrence. 20. According to the judgment of the investigator, the patient has other factors that may affect the results of the study or cause the study to be terminated halfway.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Camrelizumab
200mg, iv, 21d for a treatment cycle
Trastuzumab
8 mg/kg loading dose, followed by 6 mg/kg maintenance, iv, 21d for a treatment cycle
XELOX regimen
Oxaliplatin, 130 mg/m2, iv, d1; Capecitabine, 1000 mg/m2, po, bid, d1-d14; q3w
mFOLFOX6 regimen
Oxaliplatin, 85 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)*2d, civ, 46h; q2w
FOLFIRI regimen
Irinotecan, 180 mg/m2, iv, d1; Leucovorin, 400 mg/m2, iv, d1; 5-FU, 400mg/m2, iv, d1 followed by 1200 mg/(m2·d)*2d, civ, 46h; q2w
mXELIRI regimen
Irinotecan, 200 mg/m2, iv, d1; capecitabine, 800 mg/m2, po, bid, d1-d14; q3w
mIRIS regimen
Irinotecan, 180 mg/m2, iv, d1; Tiggio Capsules (S-1), 40-60 mg/m2, po, bid, d1-d9; q2w

Locations

Country Name City State
China 270 Dongan Road, Fudan University Shanghai Cancer Center Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate The proportion of patients with complete response or partial response according to RECIST v1.1 [ Time Frame: Approximately 24 months ]
Secondary Progression-Free Survival Time from the initiation of treatment to disease progression or any-cause death [ Time Frame: Approximately 24 months ]
Secondary Disease Control Rate The proportion of patients with complete response, partial response or stable disease according to RECIST v1.1 [ Time Frame: Approximately 24 months ]
Secondary Overall Survival Time from the initiation of treatment to any-cause death [ Time Frame: Approximately 24 months ]
Secondary Duration of Response Time from complete response or partial response to disease progression or any-cause death [ Time Frame: Approximately 24 months ]
See also
  Status Clinical Trial Phase
Recruiting NCT04552093 - Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT) Phase 2/Phase 3
Completed NCT04192565 - A Prospective Investigation of the ColubrisMX ELS System N/A
Completed NCT05178745 - A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
Recruiting NCT03561350 - Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing
Recruiting NCT06128798 - Effect of Preoperative Immunonutrition Versus Standard Oral Nutrition in Patient Undergoing Colorectal Surgery. N/A
Recruiting NCT03602677 - Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage N/A
Completed NCT03631407 - Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046) Phase 2
Withdrawn NCT04192929 - Chromoendoscopy or Narrow Band Imaging (NBI) for Improving Adenoma Detection in Colonoscopy N/A
Recruiting NCT03042091 - Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery Early Phase 1
Completed NCT02889679 - Underwater Resection of Non-pedunculated Colorectal Lesions N/A
Terminated NCT02842580 - De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer Phase 2
Completed NCT02564835 - Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer N/A
Completed NCT02503696 - Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD) N/A
Completed NCT02149108 - Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1) Phase 3
Completed NCT02599103 - The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects N/A
Completed NCT01719926 - Phase I Platinum Based Chemotherapy Plus Indomethacin Phase 1
Completed NCT01669109 - Hatha Yoga for Patients With Colorectal Cancer N/A
Recruiting NCT01428752 - Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer N/A
Completed NCT01978717 - General Anesthesia Combined With Epidural Anesthesia Mitigates the Surgical Stress-related Immunosuppression in Patients With Colorectal Cancer N/A
Completed NCT01877018 - Colorectal Cancer Screening in Primary Care N/A